# Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Source: https://onco.cc/trials/nct04181060/  
OnCo record `nct04181060` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of bevacizumab and osimertinib in lung cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer is a phase 3, randomised interventional study registered as NCT04181060 by National Cancer Institute (NCI), with a registry enrolment figure of 300 participants, started 2020-12-28 and due to reach its primary completion in 2026-12-31. Interventions recorded: Bevacizumab; Biospecimen Collection; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging; Multigated Acquisition Scan; Osimertinib. Conditions listed: Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: "* Patient must have a pathologically-confirmed diagnosis of non-squamous, non-small cell lung cancer (NSCLC)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04181060
- Phase: 3
- Setting: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT04181060: https://clinicaltrials.gov/study/NCT04181060

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Osimertinib](https://onco.cc/drugs/osimertinib/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04181060.json